Intermittent dobutamine treatment in patients with chronic refractory congestive heart failure: A randomized, double-blind, placebo-controlled study

Background: Intravenous dobutamine administration improves short-term hemodynamics in patients with severe congestive heart failure (CHF). However, the clinical benefit of periodic administration remains controversial. Objective: To evaluate the efficacy of intermittent dobutamine administration in patients with refractory CHF, Methods: Nineteen patients with New York Heart Association class III/IV ischemia-induced CHF participated in this double-blind, placebo-controlled study. All patients received intravenous dobutamine or placebo over a 24-hour period every 2 to 3 weeks for 6 months. They were also treated with angiotensin-converting enzyme inhibitors, digoxin, and diuretics. The number of admissions for CHF and mortality rate were compared; Results: Ten patients received dobutamine and nine received placebo. The pretreatment characteristics were similar in both groups. No statistically significant difference was observed between the number of admissions for CHF (p = 0.11). The median survival after enrollment was 7.97 months in the placebo group and 4.6 months in the dobutamine group. The Kaplan-Meier survival curves overlay, with no statistically significant difference between the treatment arms (p = 0.7). Conclusion: Intermittent dobutamine infusions in patients with refractory CHF have no effect on the need for hospitalization or on survival.